<html>
<head>PUBMED IDs for APR-2</head>
<body bgcolor='#C5F0F2'><h1>APR-2</h1><a href='https://pubmed.ncbi.nlm.nih.gov/12552433/'>Hookworm aspartic protease, Na-APR-2, cleaves human hemoglobin and serum proteins in a host-specific fashion.</a> January 29  2003<br><a href='https://pubmed.ncbi.nlm.nih.gov/20494116/'>The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.</a> June 19  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/20498645/'>Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.</a> August 21  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/20818419/'>PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73.</a> January 11  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21114538/'>APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells.</a> April 1  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21415220/'>PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53.</a> September 16  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21693538/'>Apoptosis-related protein-2 triggers melanoma cell death by a mechanism including both endoplasmic reticulum stress and mitochondrial dysregulation.</a> October 1  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/22085272/'>The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells.</a> December 30  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/22965953/'>Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.</a> December 20  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23355677/'>Impaired epithelial differentiation of induced pluripotent stem cells from ectodermal dysplasia-related patients is rescued by the small compound APR-246/PRIMA-1MET.</a> April 10  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/23355676/'>APR-246/PRIMA-1(MET) rescues epidermal differentiation in skin keratinocytes derived from EEC syndrome patients with p63 mutations.</a> April 10  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24030633/'>PRIMA-1Met/APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa.</a> July 8  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24129240/'>Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma.</a> January 7  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24157875/'>APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase.</a> March 13  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24768524/'>Mutant p53 reactivation by small molecules makes its way to the clinic.</a> September 18  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/26086967/'>APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.</a> February 19  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/26452133/'>PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms.</a> March 3  2015<br><a href='https://pubmed.ncbi.nlm.nih.gov/26991755/'>Anti-leukaemic effects induced by APR-246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells.</a> May 6  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27179933/'>Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.</a> February 7  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27347849/'>Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.</a> June 7  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27347838/'>Impact of Afirma gene expression classifier on cytopathology diagnosis and rate of thyroidectomy.</a> June 28  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27533246/'>Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 status.</a> August 18  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27533245/'>Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.</a> August 18  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27533158/'>Modeled Fetal Risk of Genetic Diseases Identified by Expanded Carrier Screening.</a> September 14  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27551077/'>2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells.</a> August 24  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/27615392/'>Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?</a> September 13  2016<br></body></html>
